Phase I/II Trial Of Intracerebral IL13-PE38QQR Infusions In Pediatric Patients With Recurrent Malignant Glioma.
Latest Information Update: 03 Nov 2021
At a glance
- Drugs Cintredekin besudotox (Primary)
- Indications Glioma
- Focus Adverse reactions; Therapeutic Use
- Sponsors INSYS Therapeutics, Inc
- 01 Jul 2011 Status changed from not yet recruiting to discontinued as reported by ClinicalTrials.gov (NCT00378235).
- 01 Jul 2011 Status changed from not yet recruiting to discontinued as reported by ClinicalTrials.gov (NCT00378235).
- 24 Apr 2011 Status changed from discontinued to not yet recruiting.